‘Building Better Mice’ Is the Goal of a New NCI Consortium

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

BETHESDA, Md--Forget about a better mousetrap, the National Cancer Institute wants to build better mice.

BETHESDA, Md--Forget about a better mousetrap, the National Cancer Institute wants to build better mice.

The Institute plans to fund the "Mouse Models for Human Cancer Consortium," consisting of up to six research teams with the necessary scientific and technical expertise to develop new mouse strains or improve existing mouse strains for cancer research.

The aim is to seek new animal models "to test current and future therapeutic or prevention strategies, or for early detection or diagnostic imaging," Cheryl Marks, PhD, of the NCI’s Division of Cancer Biology told the National Cancer Advisory Board.

The NCI expects to solicit and review applications, and have the consortium up and running in the spring of 1999. The consortium concept aims to encourage teams "to pursue their most innovative ideas and to implement new technologies" and to "stimulate interactions among the teams in the consortium, the NCI, and the cancer research community," Dr. Marks said.

The mouse models consortium is the first major recommendation from NCI’s Preclinical Models for Cancer Working Group. NCI is currently pursuing how best to implement other recommendations from the working group.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.